Short- and Medium-Chain Fatty Acid Profiles in Biopsy-Proven Metabolic Dysfunction-Associated Steatotic Liver Disease: A Cross-Sectional Study
Nutrients · 28.10.2026 · 18 (21) · 3548
DOI: 10.3390/nu18213548 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift Nutrients, online erschienen am 28.10.2026. Verfasst von Inmaculada Ros-Madrid und 15 weiteren Autor:innen. Beteiligte Einrichtung: Obesity, Diabetes and Metabolism Laboratory, Biomedical Research Institute of Murcia (IMIB), 30120 Murcia, Spain. Hauptthemen laut MEDLINE: Fatty Liver, Fatty Acids, Volatile, Fatty Acids, Metabolic Diseases. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Fundación Séneca - Agencia de Ciencia y Tecnología de la Región de Murcia, Fundación Séneca.
Abstract (Originalsprache)
Background/Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common metabolic liver disease with increasing prevalence worldwide. Increasing evidence suggests that short-chain fatty acids (SCFAs) play an important role in MASLD. Medium-chain fatty acids (MCFAs), although less studied, may also contribute to MASLD pathogenesis. The aim of this study was to evaluate plasma SCFA and MCFA profiles across the MASLD histological spectrum and their associations with clinical, biochemical, and histopathological features of disease severity.
Methods
We included 115 adults with obesity undergoing bariatric surgery. Intraoperative liver biopsies were assessed using the Steatosis, Activity, Fibrosis (SAF) score. Participants were classified as no MASLD (n = 26), metabolic dysfunction-associated steatotic liver (MASL; n = 42), or metabolic dysfunction-associated steatohepatitis (MASH; n = 47). Six SCFAs and two MCFAs were quantified in plasma by liquid chromatography–mass spectrometry.
Results
Patients with MASH showed lower acetate and higher hexanoate plasma levels than those without MASLD. Acetate was inversely associated with ALT, AST, GGT, glucose, HbA1c, cytokeratin-18, SAF score, steatosis and lobular inflammation, whereas hexanoate was positively associated with SAF score and lobular inflammation. Higher acetate concentrations were independently associated with lower odds of MASH (OR 0.973; p = 0.040), while ALT levels were independently associated with increased odds of MASH (OR 1.083, p = 0.001).
Conclusions
MASH in patients with obesity is characterized by a distinct circulating fatty acid profile, with reduced acetate and increased hexanoate. Lower acetate levels were independently associated with MASH and markers of metabolic and histological disease severity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Obesity, Diabetes and Metabolism Laboratory, Biomedical Research Institute of Murcia (IMIB), 30120 Murcia, Spain.
- Department of Endocrinology and Nutrition, Virgen de la Arrixaca University Hospital, 30120 Murcia, Spain.
- Department of Endocrinology and Nutrition, Regional University Hospital of Málaga, Biomedical Research Institute of Málaga and Nanomedicine Platform (IBIMA-Plataforma BIONAND), 29010 Málaga, Spain.
- Department of Anatomy and Comparative Pathology, Faculty of Veterinary Science, University of Murcia, Campus de Espinardo, 30100 Murcia, Spain.
- Facility of Innovation and Analysis in Animal Source Foodstuffs of SAIUEx, University of Extremadura, 10003 Cáceres, Spain.
- Signal Transduction and Metabolism Laboratory, Université libre de Bruxelles, 1070 Brussels, Belgium.
ORCID-Profile: Inmaculada Ros-Madrid, María A Martínez-Sánchez, Rosario P Cano-Mármol, Sara Rico-Chazarra, Alicia González-González, Carlos M Martínez, Esteban N Gurzov, Eliana Mariño, María D Frutos, Mercedes Ferrer-Gómez, José C Fernández-García, María Á Núñez-Sánchez, Bruno Ramos-Molina
Förderung
- Instituto de Salud Carlos III
- Fundación Séneca - Agencia de Ciencia y Tecnología de la Región de Murcia
- Fundación Séneca
Zitieren
APA
Ros-Madrid, I., Martínez-Sánchez, M. A., Cano-Mármol, R. P., Rico-Chazarra, S., Sánchez-Alcoholado, L., Fernández-Ruiz, V. E., González-González, A., Martínez, C. M., Silva, A., Gurzov, E. N., Mariño, E., Frutos, M. D., Ferrer-Gómez, M., Fernández-García, J. C., Núñez-Sánchez, M. Á., & Ramos-Molina, B. (2026). Short- and Medium-Chain Fatty Acid Profiles in Biopsy-Proven Metabolic Dysfunction-Associated Steatotic Liver Disease: A Cross-Sectional Study. Nutrients, 18(21), 3548. https://doi.org/10.3390/nu18213548
Vancouver
Ros-Madrid I, Martínez-Sánchez MA, Cano-Mármol RP, Rico-Chazarra S, Sánchez-Alcoholado L, Fernández-Ruiz VE, et al. Short- and Medium-Chain Fatty Acid Profiles in Biopsy-Proven Metabolic Dysfunction-Associated Steatotic Liver Disease: A Cross-Sectional Study. Nutrients. 2026;18(21):3548. doi:10.3390/nu18213548
BibTeX
@article{RosMadrid2026,
author = {Ros-Madrid, Inmaculada and Martínez-Sánchez, María A and Cano-Mármol, Rosario P and Rico-Chazarra, Sara and Sánchez-Alcoholado, Lidia and Fernández-Ruiz, Virginia E and González-González, Alicia and Martínez, Carlos M and Silva, Antonio and Gurzov, Esteban N and Mariño, Eliana and Frutos, María D and Ferrer-Gómez, Mercedes and Fernández-García, José C and Núñez-Sánchez, María Á and Ramos-Molina, Bruno},
title = {Short- and Medium-Chain Fatty Acid Profiles in Biopsy-Proven Metabolic Dysfunction-Associated Steatotic Liver Disease: A Cross-Sectional Study},
journal = {Nutrients},
year = {2026},
volume = {18},
number = {21},
pages = {3548},
doi = {10.3390/nu18213548}
}
EUVIMED